May 10, 2016 : DCMS #292

DISASTERS AVERTED — Near Miss Case Studies

Not All Neuropathies in Diabetes are Caused by Diabetes

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Eran Bashan Part 3, About Patients on Basal Bolus Therapy

HOMERUN SLIDES — Great Clinical Presentation Highlights

Diagnosing Diabetes Mellitus in Adults Part 3

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #23: Pancreatic Morphology in Normal and Diabetic States, Part 3 of 4

MOST POPULAR ARTICLES OF THE MONTH

#1 Prediabetes: How Often is the Opportunity to Intervene Missed?
#2 FDA Warns of Increased Heart-Failure Risk With Two New Diabetes Drugs
#3 Can a Common Diabetes Drug Help Heart Attack Recovery?

Patients have long told us that their grandmother lived to 100 and had diabetes for 40 years with no problems, or that no one in their family has had it before so how could they have gotten it?

These patients usually become our worst nightmares because they don’t take their condition seriously. It has only been in the last few years that we have been able to figure out why this happens.

Current research points to the Phenotype of Genotypes. To learn exactly what this means, check out this week’s Homerun Slides.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief

Female, 57 years of age, type 2 diabetes, metformin 1,000mg twice daily for 12 years, came in with weakness, anemia, tingling of fingers and toes. Her A1C had always been below 7%. Some in my office thought she had developed diabetic peripheral neuropathy. I could not disagree, but I also knew metformin can cause vitamin B12 deficiency.

In part 3 of this Exclusive Interview, Eran Bashan, CEO of Hygieia, explains about managing patients on basal bolus therapy.

In this week’s Homerun Slides, the use of genotyping in understanding the mechanisms of diabetes.

Disturbances in pancreas/islet morphology in diabetes: Type 1 diabetes (T1DM) is classically associated with autoimmune destruction of beta cells. However, the pancreas is more broadly affected, with overall pancreas size being decreased in individuals with this form of diabetes, and loss of exocrine tissue occurring close to areas of immune infiltration.

Study finds less than one quarter of patients categorized as prediabetic received prediabetes treatment from their healthcare provider.

New alert issued for type 2 patients taking saxagliptin (Onglyza, AstraZeneca) and alogliptin (Nesina, Takeda).

Better understanding of drug’s mechanism of action can lead the way to new treatment options for heart disease in diabetes patients.